JUser: :_load: Unable to load user with ID: 172

Questions? Call us at +45 25 32 17 73


About Anapa Biotech

About Anapa Biotech

Anapa Biotech A/S develops molecular tools to enhance the performance of natural nucleic acids in PCR based assays as well as hybridization.


Improving nature’s blueprint

Our scientific focus is to unlock the potential of nucleic acid intercalators. Our technology is proven to improve sensitivity, accuracy and speed when performing PCR based assays, and is a promising tool in areas like:

  • Human and veterinary diagnostics
  • Food and feed quality and safety
  • Environmental surveillance
  • Scientific research



Anapa Biotech A/S currently holds and grants licenses within a novel group of nucleic acid intercalating molecules named "Twisted Intercalating Nucleic Acids - TINA”. Read more about granting of our licenses and ordering of TINA Primers through our global distributors here.


Company history

Anapa Biotech A/S is formerly known as QuantiBact A/S. The change in name was concluded in December 2013 as the company entered the phase of commercialization.

QuantiBact A/S was founded in 2002 by Dr. Gorm Lisby and Dr. Henrik Westh from the department of Clinical Microbiology at Hvidovre University Hospital based on a patent application on a method for creation of a novel molecular quick test to detect microorganisms directly in urine in the case of suspected urinary tract infection. In 2004 "proof of technology" was made with financial support from NOVI Innovation A/S and the company was made operational in 2007 with funding from Vecata A/S and Incubation Venture A/S.

The new investors introduced a novel artificial nucleic acid - Twisted Intercalating Nucleic Acid (TINA) and QuantiBact A/S received an exclusive license to use TINA for in-vitro diagnostics. The original patent has subsequently been abandoned, but a number of new patents on molecular tools to enhance the performance of natural nucleic acids in PCR based assays as well as hybridization have been established.

Since December 2012, TINA containing oligonucleotides for research use have been available from Eurofins MWG Synthesis GmbH, Ebersberg, Germany and since June 2013 from Trilink Biotechnologies Inc in San Diego, CA, USA.